Panitumumab: an arrow on target.
Several options are available today in the treatment of advanced colorectal cancer: traditional chemotherapeutic regimens, targeted therapies, and their combinations. Panitumumab is a new, fully human anti-EGFR monoclonal antibody, what is well-tolerated, effective as a single agent in chemotherapy refractory patients and in different combinations. The clinical response is restricted to tumors with wild-type RAS, therefore the RAS status should be checked before treatment.
Kopper
László
L
Ist Department of Pathology and Experimental Cancer Research, Semmelweis University, Ulloi út 26, 1085, Budapest, Hungary. kopper@korb1.sote.hu
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D000077544:Panitumumab
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077544:Panitumumab